is a research and development pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys® drug delivery technology.
Our lead product MED2005, is a breakthrough topical treatment for erectile dysfunction currently in Phase 3 clinical trial with potential peak sales of $1bn.
Our purpose is to enhance our patients and consumers’ quality of life through deep science to enable them to live their lives to the full.
James Barder caught up with Proactive London's Andrew Scott to talk through the company's interim results.
Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain. We have a number of products in development, with MED2005 and TPR100 being the lead products.
Lead product MED2005, is the only easy to use topical treatment for erectile dysfunction.
MED2005 is a topical glyceryl trinitrate (GTN) gel which has the potential to be a highly differentiated therapy, especially for mild to moderate ED.
TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.
Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.
Current therapeutic areas are sexual health and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst seeking to minimise risk.
